Thomas A. Natoli

969 total citations
21 papers, 779 citations indexed

About

Thomas A. Natoli is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Thomas A. Natoli has authored 21 papers receiving a total of 779 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Genetics and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Thomas A. Natoli's work include Renal and related cancers (11 papers), Genetic and Kidney Cyst Diseases (10 papers) and Biomedical Research and Pathophysiology (6 papers). Thomas A. Natoli is often cited by papers focused on Renal and related cancers (11 papers), Genetic and Kidney Cyst Diseases (10 papers) and Biomedical Research and Pathophysiology (6 papers). Thomas A. Natoli collaborates with scholars based in United States, France and Finland. Thomas A. Natoli's co-authors include Oxana Ibraghimov‐Beskrovnaya, Jordan A. Kreidberg, Nikolay O. Bukanov, Steven C. Pruitt, Laurie A. Smith, Steven Ledbetter, Hervé Husson, David E. Housman, Ryan J. Russo and Michael J. Donovan and has published in prestigious journals such as Nature Medicine, Blood and Molecular and Cellular Biology.

In The Last Decade

Thomas A. Natoli

20 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas A. Natoli United States 17 643 351 113 111 77 21 779
Véronique Chauvet France 12 554 0.9× 554 1.6× 48 0.4× 265 2.4× 75 1.0× 20 811
Akie Nakamura Japan 19 524 0.8× 532 1.5× 82 0.7× 34 0.3× 197 2.6× 77 952
Moumita Chaki United States 16 637 1.0× 532 1.5× 52 0.5× 77 0.7× 131 1.7× 26 873
China Nagano Japan 15 361 0.6× 154 0.4× 87 0.8× 63 0.6× 37 0.5× 79 630
Moez Gribaa Tunisia 15 347 0.5× 279 0.8× 28 0.2× 27 0.2× 162 2.1× 51 679
Katherine I. Swenson-Fields United States 8 355 0.6× 409 1.2× 47 0.4× 123 1.1× 74 1.0× 9 582
Noriyuki Sugiyama Japan 12 531 0.8× 295 0.8× 33 0.3× 20 0.2× 36 0.5× 16 690
Lorine Wilkinson Australia 14 439 0.7× 111 0.3× 123 1.1× 10 0.1× 166 2.2× 23 674
Holly Dushkin United States 12 179 0.3× 126 0.4× 69 0.6× 46 0.4× 34 0.4× 18 455

Countries citing papers authored by Thomas A. Natoli

Since Specialization
Citations

This map shows the geographic impact of Thomas A. Natoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Natoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Natoli more than expected).

Fields of papers citing papers by Thomas A. Natoli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Natoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Natoli. The network helps show where Thomas A. Natoli may publish in the future.

Co-authorship network of co-authors of Thomas A. Natoli

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Natoli. A scholar is included among the top collaborators of Thomas A. Natoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Natoli. Thomas A. Natoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Natoli, Thomas A., Puneet Khandelwal, Pavlos Pissios, et al.. (2024). VEPTP inhibition with an extracellular domain targeting antibody did not restore albuminuria in a mouse model of diabetic kidney disease. Physiological Reports. 12(18). e70058–e70058.
2.
Natoli, Thomas A., Vijay Modur, & Oxana Ibraghimov‐Beskrovnaya. (2020). Glycosphingolipid metabolism and polycystic kidney disease. Cellular Signalling. 69. 109526–109526. 20 indexed citations
3.
Husson, Hervé, Nikolay O. Bukanov, Sarah Moreno, et al.. (2020). Correction of cilia structure and function alleviates multi-organ pathology in Bardet–Biedl syndrome mice. Human Molecular Genetics. 29(15). 2508–2522. 10 indexed citations
4.
Bracken, Christina, Philippe Beauverger, Olivier Duclos, et al.. (2016). CaMKII as a pathological mediator of ER stress, oxidative stress, and mitochondrial dysfunction in a murine model of nephronophthisis. American Journal of Physiology-Renal Physiology. 310(11). F1414–F1422. 29 indexed citations
5.
Moreno, Sarah, Laurie A. Smith, Hervé Husson, et al.. (2016). Differences in the timing and magnitude ofPkd1gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD. Physiological Reports. 4(12). e12846–e12846. 18 indexed citations
6.
Bukanov, Nikolay O., Sarah Moreno, Thomas A. Natoli, et al.. (2012). CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 11(21). 4040–4046. 51 indexed citations
7.
Natoli, Thomas A., Hervé Husson, Laurie A. Smith, et al.. (2012). Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Human Molecular Genetics. 21(15). 3397–3407. 33 indexed citations
8.
Ibraghimov‐Beskrovnaya, Oxana & Thomas A. Natoli. (2011). mTOR signaling in polycystic kidney disease. Trends in Molecular Medicine. 17(11). 625–633. 70 indexed citations
9.
Natoli, Thomas A., Laurie A. Smith, Bing Wang, et al.. (2010). Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nature Medicine. 16(7). 788–792. 139 indexed citations
10.
Natoli, Thomas A., William R. Dackowski, Laurie A. Smith, et al.. (2007). Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures. American Journal of Physiology-Renal Physiology. 294(1). F73–F83. 41 indexed citations
11.
Natoli, Thomas A., Alex Bortvin, Mary Taglienti, et al.. (2004). Wt1 functions in the development of germ cells in addition to somatic cell lineages of the testis. Developmental Biology. 268(2). 429–440. 30 indexed citations
12.
Pruitt, Steven C., et al.. (2004). Hox/Pbx and Brn binding sites mediate Pax3 expression in vitro and in vivo. Gene Expression Patterns. 4(6). 671–685. 30 indexed citations
13.
Springett, Gregory M., Helen Rayburn, Thomas A. Natoli, et al.. (2003). Role of the WT1 tumor suppressor in murine hematopoiesis. Blood. 101(7). 2570–2574. 44 indexed citations
14.
Natoli, Thomas A., Jing Liu, Vera Eremina, et al.. (2002). A Mutant Form of the Wilms’ Tumor Suppressor Gene WT1 Observed in Denys-Drash Syndrome Interferes with Glomerular Capillary Development. Journal of the American Society of Nephrology. 13(8). 2058–2067. 46 indexed citations
15.
Natoli, Thomas A., et al.. (2002). A Mammal-Specific Exon of WT1 Is Not Required for Development or Fertility. Molecular and Cellular Biology. 22(12). 4433–4438. 47 indexed citations
16.
Kreidberg, Jordan A., et al.. (1999). Coordinate action ofWt1 and a modifier gene supports embryonic survival in the oviduct. Molecular Reproduction and Development. 52(4). 366–375. 26 indexed citations
17.
Donovan, Michael J., Thomas A. Natoli, Kirsi Sainio, et al.. (1999). Initial differentiation of the metanephric mesenchyme is independent of WT1 and the ureteric bud. Developmental Genetics. 24(3-4). 252–262. 80 indexed citations
18.
Donovan, Michael J., Thomas A. Natoli, Kirsi Sainio, et al.. (1999). Initial differentiation of the metanephric mesenchyme is independent of WT1 and the ureteric bud. Developmental Genetics. 24(34). 252–262. 3 indexed citations
19.
Natoli, Thomas A., et al.. (1997). Positive and negative DNA sequence elements are required to establish the pattern of Pax3 expression. Development. 124(3). 617–626. 39 indexed citations
20.
Pruitt, Steven C. & Thomas A. Natoli. (1992). Inhibition of differentiation by leukemia inhibitory factor distinguishes two induction pathways in P19 embryonal carcinoma cells. Differentiation. 50(1). 57–65. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique Chauvet Breakdown of academic impact, for papers by Akie Nakamura Breakdown of academic impact, for papers by Moumita Chaki Breakdown of academic impact, for papers by China Nagano Breakdown of academic impact, for papers by Moez Gribaa Breakdown of academic impact, for papers by Katherine I. Swenson-Fields Breakdown of academic impact, for papers by Noriyuki Sugiyama Breakdown of academic impact, for papers by Lorine Wilkinson Breakdown of academic impact, for papers by Holly Dushkin
Rankless by CCL
2026